Stockscreener 앱 받기
1.35
0.74%
-0.01
시장 영업 전:
1.38
0.03
+2.22%
전일 마감가:
$1.36
열려 있는:
$1.37
하루 거래량:
1.39M
Relative Volume:
2.17
시가총액:
$86.72M
수익:
-
순이익/손실:
$-71.17M
주가수익비율:
-0.9712
EPS:
-1.39
순현금흐름:
$-70.97M
1주 성능:
-10.60%
1개월 성능:
-54.85%
6개월 성능:
-74.67%
1년 성능:
-68.68%
1일 변동 폭
$1.33
$1.44
1주일 범위
$1.32
$1.55
52주 변동 폭
$1.32
$7.795
이노즈메 Stock (INZY) Company Profile
명칭
Inozyme Pharma Inc
전화
857-330-4340
주소
321 SUMMER STREET, BOSTON
INZY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INZY
Inozyme Pharma Inc
|
1.35 | 86.72M | 0 | -71.17M | -70.97M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
이노즈메 Stock (INZY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-12 | 개시 | Raymond James | Outperform |
| 2024-09-12 | 개시 | Stifel | Buy |
| 2024-08-13 | 재개 | Jefferies | Buy |
| 2024-05-30 | 개시 | Wells Fargo | Overweight |
| 2023-03-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-05-26 | 개시 | Jefferies | Hold |
| 2022-02-07 | 개시 | H.C. Wainwright | Buy |
| 2021-11-29 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | BofA Securities | Buy |
| 2020-08-18 | 개시 | Cowen | Outperform |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-18 | 개시 | Wedbush | Outperform |
모두보기
이노즈메 주식(INZY)의 최신 뉴스
Inozyme Pharma, Inc. (NASDAQ:INZY) Short Interest Update - MarketBeat
Barclays PLC Increases Stock Position in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma (NASDAQ:INZY) Price Target Cut to $30.00 by Analysts at Piper Sandler - Defense World
Inozyme Pharma (NASDAQ:INZY) Price Target Lowered to $11.00 at Wells Fargo & Company - Defense World
Inozyme Pharma (NASDAQ:INZY) Given New $11.00 Price Target at Wells Fargo & Company - MarketBeat
Inozyme shares remain Outperform at Raymond James, target reduced amid study focus - Investing.com Australia
Inozyme shares remain Outperform at Raymond James, target reduced amid study focus By Investing.com - Investing.com South Africa
Inozyme Pharma (NASDAQ:INZY) Announces Positive Interim Data and Program Updates**SAN FRANCISCO, Jan 10, 2025 /PRNewswire/ — Inozyme Pharma, Inc. (NASDAQ:INZY) revealed favorable results from its recent interim data analysis and provided - Defense World
Seres Therapeutics Provides Corporate Updates and Financial Results - Defense World
HC Wainwright Predicts Inozyme Pharma Q1 Earnings - Defense World
HC Wainwright Comments on Inozyme Pharma Q1 Earnings - MarketBeat
Wedbush Reaffirms “Outperform” Rating for Inozyme Pharma (NASDAQ:INZY) - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Inozyme Pharma (NASDAQ:INZY) Stock - Defense World
Inozyme Pharma stock hits 52-week low at $2.37 amid market challenges - Investing.com Canada
Analyzing Inozyme Pharma (NASDAQ:INZY) & Williston (OTCMKTS:WHCA) - Defense World
Inozyme Pharma Announces Positive Interim Data for INZ-701 - GlobeNewswire
Wedbush Reiterates "Outperform" Rating for Inozyme Pharma (NASDAQ:INZY) - MarketBeat
Inozyme reports promising data on rare disease treatments By Investing.com - Investing.com Canada
Inozyme Pharma (NASDAQ:INZY) Price Target Raised to $16.00 - MarketBeat
Inozyme Pharma stock hits 52-week low at $2.37 amid market challenges By Investing.com - Investing.com South Africa
Inozyme reports promising data on rare disease treatments - Investing.com
Inozyme Pharma Advances with Promising Trial Results - TipRanks
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with - The Bakersfield Californian
Inozyme's INZ-701 Treatment Boosts Infant Survival Rate to 80% in ENPP1 Deficiency Trial - StockTitan
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Barclays PLC Buys 55,497 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Geode Capital Management LLC Boosts Stake in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
State Street Corp Acquires 50,386 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Recommendation of “Buy” by Analysts - Defense World
Inozyme Pharma (NASDAQ:INZY) Coverage Initiated at Raymond James - Defense World
Raymond James Begins Coverage on Inozyme Pharma (NASDAQ:INZY) - MarketBeat
Jefferies initiates Buy rating on Inozyme Pharma stock, highlights potential of INZ-701 - Investing.com
Affinity Asset Advisors, LLC Increases Stake in Inozyme Pharma I - GuruFocus.com
Inozyme Pharma stock hits 52-week low at $2.53 amid market challenges - Investing.com Canada
Eventide Asset Management LLC Purchases 198,216 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - MarketBeat
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Inozyme Pharma to Present at Piper Sandler Healthcare Conference | INZY Stock News - StockTitan
Inozyme Pharma stock hits 52-week low at $2.6 amid market challenges - Investing.com Canada
Analyzing Inozyme Pharma (NASDAQ:INZY) and Theratechnologies (NASDAQ:THTX) - Defense World
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks - MSN
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet? - Simply Wall St
이노즈메 (INZY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):